Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av oral TP-3654 hos pasienter med myelofibrose

30. september 2026 oppdatert av: Sumitomo Pharma America, Inc.

En fase 1/2, åpen etikett, doseøkning, sikkerhet, farmakokinetisk og farmakodynamisk studie av oral TP-3654 hos pasienter med middels eller høyrisiko primær eller sekundær myelofibrose

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.

Studieoversikt

Detaljert beskrivelse

Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive treatment with a JAK inhibitor.

Arm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response.

Arm 3 will enroll patients who have been previously treated with a JAK inhibitor (except momelotinib)

Studietype

Intervensjonell

Registrering (Antatt)

240

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Adelaide, Australia
        • Rekruttering
        • Icon Cancer Centre (Ashford Cancer Centre Research)
        • Ta kontakt med:
    • South Australia
      • Adelaide, South Australia, Australia
    • Victoria
      • Box Hill, Victoria, Australia
        • Rekruttering
        • Eastern Health Box Hill Hospital
        • Ta kontakt med:
          • SMPA Investigative Site
      • Clayton, Victoria, Australia
        • Rekruttering
        • Monash University
        • Ta kontakt med:
          • SMPA Investigative Site
      • Fitzroy, Victoria, Australia
        • Rekruttering
        • St Vincent's Hospital Melbourne
        • Ta kontakt med:
          • SMPA Investigative Site
      • Melbourne, Victoria, Australia
        • Rekruttering
        • Peter McCallum Center
        • Ta kontakt med:
          • SMPA Investigative Site
      • Richmond, Victoria, Australia
        • Rekruttering
        • Epworth Healthcare
        • Ta kontakt med:
          • SMPA Investigative Site
      • Antwerp, Belgia, 2020
        • Rekruttering
        • ZNA Cadix
        • Ta kontakt med:
          • SMPA Investigative Site
      • Antwerp, Belgia, 2030
        • Rekruttering
        • ZNA Middelheim
        • Ta kontakt med:
          • SMPA Investigative Site
      • Ghent, Belgia, 9000
        • Rekruttering
        • Universitair Ziekenhuis Gent
        • Ta kontakt med:
          • SMPA Investigative Site
      • Liège, Belgia, 4000
        • Rekruttering
        • CHU de Liege
        • Ta kontakt med:
          • SMPA Investigative Site
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Belgia, 3000
        • Rekruttering
        • University Hospitals Leuven
        • Ta kontakt med:
          • SMPA Investigative Site
    • Alberta
    • British Columbia
      • Vancouver, British Columbia, Canada, V6T 1Z3
        • Rekruttering
        • University of British Columbia
        • Ta kontakt med:
          • SMPA Investigative Site
      • Vancouver, British Columbia, Canada, V6T 1Z3
        • Rekruttering
        • St. Paul's Hospital Hematology/Oncology Research
        • Ta kontakt med:
    • Ontario
      • Hamilton, Ontario, Canada, L8V 5C2
        • Rekruttering
        • Juravinski Cancer Center
        • Ta kontakt med:
          • SMPA Investigative Site
      • Toronto, Ontario, Canada, M5G 2M9
        • Rekruttering
        • Princess Margaret Cancer Center
        • Ta kontakt med:
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Rekruttering
        • Jewish General Hospital
        • Ta kontakt med:
          • SMPA Investigative Site
    • Alabama
      • Birmingham, Alabama, Forente stater, 35294
        • Rekruttering
        • University of Alabama
        • Ta kontakt med:
          • Tiffany Hill
          • Telefonnummer: 205-934-9591
    • Arizona
      • Tucson, Arizona, Forente stater, 85724
        • Rekruttering
        • The University of Arizona Cancer Center
        • Ta kontakt med:
    • California
      • Duarte, California, Forente stater, 91010
        • Rekruttering
        • City of Hope
        • Ta kontakt med:
      • Los Angeles, California, Forente stater, 90033
        • Rekruttering
        • University of Southern California
        • Ta kontakt med:
      • Newport Beach, California, Forente stater, 92663
        • Rekruttering
        • Hoag Family Cancer Institute
        • Ta kontakt med:
    • Colorado
      • Denver, Colorado, Forente stater, 80218
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06510
        • Rekruttering
        • Yale School of Medicine
        • Ta kontakt med:
    • Florida
      • Gainesville, Florida, Forente stater, 32608
        • Fullført
        • University of Florida Health Shands Cancer Hospital
      • Miami, Florida, Forente stater, 33136
        • Rekruttering
        • University of Miami
        • Ta kontakt med:
      • Miami, Florida, Forente stater, 33176
        • Rekruttering
        • Baptist Health - Miami Cancer Institute
        • Ta kontakt med:
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
    • Illinois
      • Chicago, Illinois, Forente stater, 60637
    • Maryland
      • Baltimore, Maryland, Forente stater, 21201
        • Rekruttering
        • University of Maryland
        • Ta kontakt med:
          • Maria Baer, MD
          • Telefonnummer: 410-328-8708
          • E-post: mbaer@umm.edu
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Rekruttering
        • Massachusetts General Hospital
        • Ta kontakt med:
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • Rekruttering
        • University of Michigan
        • Ta kontakt med:
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55455
        • Rekruttering
        • University of Minnesota
        • Ta kontakt med:
    • Missouri
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Washington University of Medicine
        • Ta kontakt med:
    • New Jersey
      • Hackensack, New Jersey, Forente stater, 07601
        • Rekruttering
        • John Theurer Cancer Center at Hackensack University Medical Center
        • Ta kontakt med:
    • New York
      • Buffalo, New York, Forente stater, 14263
        • Fullført
        • Roswell Park Comprehensive Cancer Center
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center
        • Ta kontakt med:
      • New York, New York, Forente stater, 10029
        • Rekruttering
        • Icahn School of Medicine at Mount Sinai
        • Ta kontakt med:
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • Weill Cornell Medical Center
        • Ta kontakt med:
      • The Bronx, New York, Forente stater, 10461
    • North Carolina
      • Durham, North Carolina, Forente stater, 27710
    • Ohio
      • Columbus, Ohio, Forente stater, 43210
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29425
        • Rekruttering
        • Medical University of South Carolina
        • Ta kontakt med:
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37232
        • Rekruttering
        • Vanderbilt University
        • Ta kontakt med:
          • SMPA Investigative Site
      • Nashville, Tennessee, Forente stater, 37203
    • Texas
      • Houston, Texas, Forente stater, 77054
        • Rekruttering
        • MD Anderson Cancer Center
        • Ta kontakt med:
    • Utah
      • Salt Lake City, Utah, Forente stater, 84112
        • Rekruttering
        • Huntsman Cancer Institute
        • Ta kontakt med:
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22903
        • Rekruttering
        • University of Virginia Cancer Center
        • Ta kontakt med:
    • Washington
      • Seattle, Washington, Forente stater, 98109
        • Rekruttering
        • University of Washington - Fred Hutchinson Cancer Center
        • Ta kontakt med:
      • Amiens, Frankrike, 80054
        • Rekruttering
        • Centre Hospitalier Universitaire D'Amiens
        • Ta kontakt med:
          • SMPA Investigative Site
      • Angers, Frankrike, 9000
        • Rekruttering
        • CHU Angers
        • Ta kontakt med:
          • SMPA Investigative Site
      • Lyon, Frankrike, 69495
        • Rekruttering
        • Centre Hospitalier Lyon Sud
        • Ta kontakt med:
          • SMPA Investigative Site
      • Nice, Frankrike, 06200
        • Rekruttering
        • Hospitalier Universitaire (CHU) de Nice - Hopital de l'Archet
        • Ta kontakt med:
          • SMPA Investigative Site
      • Nîmes, Frankrike, 30029
        • Rekruttering
        • Institut de cancerologie du Gard
        • Ta kontakt med:
          • SMPA Investigative Site
      • Nîmes, Frankrike
        • Rekruttering
        • Institut de cancerologie du Gard
        • Ta kontakt med:
          • SMPA Investigative Site
      • Paris, Frankrike, 75010
        • Rekruttering
        • Hospital Saint Louis
        • Ta kontakt med:
          • SMPA Investigative Site
      • Poitiers, Frankrike, 86021
        • Rekruttering
        • University Hospital of Poitiers
        • Ta kontakt med:
          • SMPA Investigative Site
      • Villejuif, Frankrike, 94805
        • Rekruttering
        • Institut Gustave Roussy
        • Ta kontakt med:
          • SMPA Investigative Site
      • Alessandria, Italia, 15121
        • Rekruttering
        • Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
        • Ta kontakt med:
          • SMPA Investigative Site
      • Aviano, Italia, 33081
        • Rekruttering
        • Istituto Nazionale Tumori, IRCCS Centro di Riferimento Oncologico di Aviano
      • Bologna, Italia, 40138
        • Rekruttering
        • IRCCS Azienda Ospedaliero -Universitaria Di Bologna - Dipartimento Malattie Oncologiche ed Ematologiche - UO Ematologia
        • Ta kontakt med:
          • SMPA Investigative Site
      • Brescia, Italia
        • Rekruttering
        • ASST - Spedali Civili di Brescia
        • Ta kontakt med:
          • SMPA Investigative Site
      • Meldola, Italia, 47014
        • Rekruttering
        • IRCCS istituto Romagnolo per lo studio dei tumori "Dino Amadori"
        • Ta kontakt med:
          • SMPA Investigative Site
      • Milan, Italia, 20122
        • Rekruttering
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
        • Ta kontakt med:
          • SMPA Investigative Site
      • Torino, Italia, 10126
        • Rekruttering
        • Azienda Ospedaliera Universitaria Citta' Della Salute E della Scienza di Torino
        • Ta kontakt med:
          • SMPA Investigative Site
      • Aichi, Japan
      • Aomori, Japan
        • Rekruttering
        • Aomori Prefectural Central Hospital
        • Ta kontakt med:
      • Chiba, Japan
        • Rekruttering
        • National Cancer Center Hospital East
        • Ta kontakt med:
      • Fukuoka, Japan
      • Hokkaido, Japan
        • Rekruttering
        • Hokkaido University Hospital
        • Ta kontakt med:
      • Kamakura, Japan, 247-8533
        • Rekruttering
        • Shonan Kamakura General Hospital
        • Ta kontakt med:
      • Miyazaki, Japan
        • Rekruttering
        • University of Miyazaki Hospital
        • Ta kontakt med:
      • Okayama, Japan
        • Rekruttering
        • Okayama University Hospital
        • Ta kontakt med:
      • Osaka, Japan
        • Rekruttering
        • The University of Osaka Hospital
        • Ta kontakt med:
          • Michiko Ichii, MD
          • Telefonnummer: 06-6879-5111
      • Saitama, Japan
        • Fullført
        • Saitama Medical Center
      • Sendai, Japan
        • Rekruttering
        • Tohoku University Hospital
        • Ta kontakt med:
          • Noriko Fukuhara, MD
          • Telefonnummer: 022-717-7000
      • Shizuoka, Japan
        • Fullført
        • Shizuoka Cancer Center
      • Tokyo, Japan, 160-0023
        • Rekruttering
        • Tokyo Medical University Hospital
        • Ta kontakt med:
      • Tokyo, Japan
        • Rekruttering
        • Juntendo University Hospital
        • Ta kontakt med:
      • Tokyo, Japan, 179-0072
        • Rekruttering
        • Nerima Hikarigaoka Hospital
        • Ta kontakt med:
      • Tsu, Japan
      • Barcelona, Spania
        • Rekruttering
        • Hospital Universitario y Politecnico La Fe
        • Ta kontakt med:
          • SMPA Investigative Site
      • Barcelona, Spania
        • Rekruttering
        • Institut Catala d'Oncologia
        • Ta kontakt med:
          • SMPA Investigative Site
      • Salamanca, Spania
        • Rekruttering
        • Hospital Universitario de Salamanca
        • Ta kontakt med:
          • SMPA Investigative Site
      • Lincoln, Storbritannia
        • Rekruttering
        • Lincoln County Hospital
        • Ta kontakt med:
          • SMPA Investigative Site
      • Lincoln, Storbritannia
        • Rekruttering
        • United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital
        • Ta kontakt med:
          • SMPA Investigative Site
      • London, Storbritannia
        • Rekruttering
        • University College London Hospital's NHS foundation Trust
        • Ta kontakt med:
          • SMPA Investigative Site
      • Oxford, Storbritannia
        • Rekruttering
        • Oxford University Hospitals NHS Foundation
        • Ta kontakt med:
          • SMPA Investigative Site
      • Halle, Tyskland
        • Rekruttering
        • Universitätsmedizin Halle
        • Ta kontakt med:
          • SMPA Investigative Site
      • Lübeck, Tyskland
        • Rekruttering
        • Universitätsklinikum Schleswig-Holstein
        • Ta kontakt med:
          • SMPA Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Patients must meet all of the following inclusion criteria to be eligible:

Nuvisertib (TP-3654) Monotherapy Arm:

  • Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF and intermediate or high-risk primary or secondary MF
  • Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor
  • Fulfill the following clinical laboratory parameters:
  • Platelet count ≥ 25 x 10^9 /L, without assistance of growth factors or platelet transfusions
  • ANC ≥ 1 x 10^9/L without assistance of granulocyte growth factors
  • Peripheral blood blast count < 5%
  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months
  • Adequate renal function
  • Adequate hepatic function
  • Adequate coagulation function
  • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.
  • Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF
  • Dose expansion: At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF

Nuvisertib (TP-3654) + Ruxolitinib Arm:

  • Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF and intermediate or high-risk primary or secondary MF
  • On ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib, but has either lost response or had a suboptimal or plateau in response
  • Fulfills the following clinical laboratory parameters:
  • Platelet count ≥ 50 × 10^9/L (without assistance of growth factors or platelet transfusions)
  • ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
  • Peripheral blood blast count < 5% at screening
  • Adequate renal function
  • Adequate hepatic function
  • Adequate coagulation function
  • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
  • At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months

Nuvisertib (TP-3654) + Momelotinib Arm

  • Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF and intermediate or high-risk primary or secondary MF
  • Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma
  • Fulfills the following clinical laboratory parameters:
  • Anemic, defined as Hb <10 g/dL or requiring RBC transfusion at baseline
  • Platelet count ≥ 50 × 109/L (without assistance of growth factors or platelet transfusions)
  • ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
  • Peripheral blood blast count < 5% at screening
  • Adequate renal function
  • Adequate hepatic function
  • Adequate coagulation function
  • Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
  • At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
  • ECOG performance status ≤ 1
  • Life expectancy ≥ 6 months

Patients meeting any one of these exclusion criteria will be prohibited from participating in this study:

Nuvisertib (TP-3654) Monotherapy Arm:

  • Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
  • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or not recovered adequately from from surgery prior to first dose.
  • Splenic irradiation within 6 months prior to Screening or prior splenectomy.
  • Prior allogeneic stem cell transplant within the last 6 months.
  • Eligible for allogeneic bone marrow or stem cell transplantation.
  • Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment
  • History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF) < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.
  • Corrected QT interval > 480msec.
  • Prior or concurrent malignancy that could interfere with the investigational regime.
  • Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.
  • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
  • Exhibited allergic reactions or sensitivity to nuvisertib, or similar compound.
  • Medical condition or GI tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.
  • Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding.
  • Pregnant or breastfeeding
  • Currently receiving any other investigational agent.

Nuvisertib (TP-3654) + Ruxolitinib Arm:

  • Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Prior treatment with nuvisertib is not allowed. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
  • Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)
  • Known allergic reactions or sensitivity to nuvisertib, or similar compound.
  • Splenic irradiation within 6 months prior to Screening or prior splenectomy
  • Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
  • Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.)
  • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately prior to first dose.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
  • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
  • Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).
  • Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
  • History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF <45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
  • Corrected QTcF of > 480 msec
  • Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
  • History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
  • Pregnant or breastfeeding

Nuvisertib (TP-3654) + Momelotinib Arm:

  • Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib or nuvisertib is not allowed; in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper; hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
  • Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
  • Known allergic reactions or sensitivity to nuvisertib, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention
  • Splenic irradiation within 6 months prior to screening or prior splenectomy
  • Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
  • Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).
  • Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately from surgery prior to first dose.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
  • Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
  • Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)
  • Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
  • Presence of Grade ≥ 2 peripheral neuropathy
  • History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
  • Corrected QTcF of > 480 msec
  • Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
  • History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
  • Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
  • Pregnant or breastfeeding

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm 1: nuvisertib (TP-3654)

Oral PIM Inhibitor

Andre navn:
  • TP-3654
Eksperimentell: Arm 2: nuvisertib (TP-3654) lagt til ruxolitinib

Oral PIM Inhibitor

Andre navn:
  • TP-3654

Oral JAK inhibitor

Andre navn:
  • Jakafi
Eksperimentell: Arm 3: nuvisertib (TP-3654) i kombinasjon med momelotinib

Oral PIM Inhibitor

Andre navn:
  • TP-3654

Oral JAK inhibitor

Andre navn:
  • Ojjaara

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Determine the incidence of dose-limiting toxicities (DLTs)
Tidsramme: 28 days

Number of participants with DLTs

28 days
Determine the incidence of treatment emergent adverse events
Tidsramme: From start of treatment to end of study

Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events

From start of treatment to end of study
Assess patients for any evidence of preliminary activity by determining the number of patients with ≥ 35% spleen volume reduction (SVR35)
Tidsramme: From start of treatment to end of study

Number of participants with ≥ 35% spleen volume reduction (SVR35)

From start of treatment to end of study

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of participants achieving objective response by IWG-MRT response criteria
Tidsramme: From start of treatment to end of study

Number of participants achieving complete remission, partial remission, clinical improvement, progressive disease and stable disease.

From start of treatment to end of study
Number of participants who have ≥ 25% spleen volume reduction
Tidsramme: Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.

Number of participants who have ≥ 25% spleen volume reduction compared to baseline

Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
Number of participants with ≥ 50% improvement in total symptom score (TSS50) at week 24
Tidsramme: 24 weeks

Number of participants who have ≥ 50% total symptom score reduction by MFSAF compared to baseline after 24 weeks of treatment.

24 weeks
Determine the change in Patient Global Impression of Change (PGIC) at week 24 through end of study.
Tidsramme: After 24 weeks of treatment to end of study

Change in PGIC score

After 24 weeks of treatment to end of study
Determine the incidence of QT interval changes
Tidsramme: 25 hours

Changes in QT interval and heart rhythm

25 hours
Establish the half-life (t½) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Tidsramme: 24 hours

The estimate of time for the nuvisertib concentration or amount to be reduced by half

24 hours
Establish the Area under the plasma concentration versus time curve (AUC) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Tidsramme: 24 hours

The amount of drug exposure over 24 hours period after administration

24 hours
Establish the Peak Plasma Concentration (Cmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Tidsramme: 24 hours

The maximum nuvisertib concentration after administration

24 hours
Establish the Time of Maximum concentration observed (tmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Tidsramme: 24 hours

The time to reach maximum nuvisertib concentration

24 hours

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Antall pasienter med reduksjon i benmargsfibrose
Tidsramme: Hver 24. uke til slutten av studiet
Hver 24. uke til slutten av studiet
Nuvisertib kombinasjonsarmer: Vurder økningen i hemoglobin ≥1,5 eller ≥ 2 g/dL fra baseline
Tidsramme: Fra behandlingsstart til studieslutt
Fra behandlingsstart til studieslutt
Nuvisertib-kombinasjonsarmer: Vurder uavhengig status for transfusjon av røde blodlegemer eller endring av krav
Tidsramme: Fra behandlingsstart til studieslutt
Fra behandlingsstart til studieslutt
Nuvisertib monoterapi: Endringer i blodplatetall over tid hos pasienter med baseline blodplatetall <100 x 10^9/l
Tidsramme: Fra behandlingsstart til slutt på studien
Fra behandlingsstart til slutt på studien
Study potential pharmacodynamic (PD) markers of nuvisertib
Tidsramme: 12 months

Evaluate exploratory biomarkers, including change in protein phosphorylation and inflammatory cytokines, in peripheral blood samples and bone marrow biopsy samples.

12 months
Establish overall survival
Tidsramme: From start of treatment to end of study

The time interval from treatment start date to date of death from any cause

From start of treatment to end of study

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

16. desember 2019

Primær fullføring (Antatt)

30. april 2027

Studiet fullført (Antatt)

30. april 2030

Datoer for studieregistrering

Først innsendt

8. november 2019

Først innsendt som oppfylte QC-kriteriene

22. november 2019

Først lagt ut (Faktiske)

25. november 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere